Recent developments in ruthenium anticancer drugs
Top Cited Papers
Open Access
- 1 January 2009
- journal article
- review article
- Published by Oxford University Press (OUP) in Metallomics
- Vol. 1 (6), 458-470
- https://doi.org/10.1039/b904071d
Abstract
Interest in Ru anticancer drugs has been growing rapidly since NAMI-A ((ImH+)[RuIIICl4(Im)(S-dmso)], where Im = imidazole and S-dmso = S-bound dimethylsulfoxide) or KP1019 ((IndH+)[RuIIICl4(Ind)2], where Ind = indazole) have successfully completed phase I clinical trials and an array of other Ru complexes have shown promise for future development. Herein, the recent literature is reviewed critically to ascertain likely mechanisms of action of Ru-based anticancer drugs, with the emphasis on their reactions with biological media. The most likely interactions of Ru complexes are with: (i) albumin and transferrin in blood plasma, the former serving as a Ru depot, and the latter possibly providing active transport of Ru into cells; (ii) collagens of the extracellular matrix and actins on the cell surface, which are likely to be involved in the specific anti-metastatic action of Ru complexes; (iii) regulatory enzymes within the cell membrane and/or in the cytoplasm; and (iv) DNA in the cell nucleus. Some types of Ru complexes can also promote the intracellular formation of free radical species, either through irradiation (photodynamic therapy), or through reactions with cellular reductants. The metabolic pathways involve competition among reduction, aquation, and hydrolysis in the extracellular medium; binding to transport proteins, the extracellular matrix, and cell-surface biomolecules; and diffusion into cells; with the extent to which individual drugs participate in various steps along these pathways being crucial factors in determining whether they are mainly anti-metastatic or cytotoxic. This diversity of modes of action of Ru anticancer drugs is also likely to enhance their anticancer activities and to reduce the potential for them to develop tumour resistance. New approaches to metabolic studies, such as X-ray absorption spectroscopy and X-ray fluorescence microscopy, are required to provide further mechanistic insights, which could lead to the rational design of improved Ru anticancer drugs.Keywords
This publication has 137 references indexed in Scilit:
- Ruthenium polypyridyl complexes and their modes of interaction with DNA: Is there a correlation between these interactions and the antitumor activity of the compounds?JBIC Journal of Biological Inorganic Chemistry, 2008
- Photoactive ruthenium nitrosyls: Effects of light and potential application as NO donorsCoordination Chemistry Reviews, 2008
- Targeting Large Kinase Active Site with Rigid, Bulky Octahedral Ruthenium ComplexesJournal of the American Chemical Society, 2008
- New trends for metal complexes with anticancer activityCurrent Opinion in Chemical Biology, 2008
- Kinetics and mechanism of the reduction of (ImH)[trans-RuCl4(dmso)(Im)] by ascorbic acid in acidic aqueous solutionJBIC Journal of Biological Inorganic Chemistry, 2007
- Time-dependent uptake, distribution and biotransformation of chromium(VI) in individual and bulk human lung cells: application of synchrotron radiation techniquesJBIC Journal of Biological Inorganic Chemistry, 2005
- Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-AEuropean Journal of Cancer, 2004
- Binding of ruthenium(III) anti-tumor drugs to human lactoferrin probed by high resolution X-ray crystallographic structure analysesJBIC Journal of Biological Inorganic Chemistry, 1996
- Anti-leukaemic action of RuCl2(DMSO)4 isomers and prevention of brain involvement on P388 leukaemia and on P388DDP sublineEuropean Journal of Cancer, 1993
- Fluorescence and kinetic properties of Ru(III) (NH3)5 modified transferrinBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1991